

NOVAVAX INC
Form 8-K
July 21, 2004

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT PURSUANT TO 13 or 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): July 19, 2004

NOVAVAX, INC.

(Exact name of registrant as specified in its charter)

| | | |
|---|---|---|
| <u>Delaware</u> (State or other jurisdiction of incorporation or organization) | <u>0-26770</u> (Commission File No.) | <u>22-2816046</u> (I.R.S. Employer Identification No.) |
|---|---|---|

| | |
|--|-----------------------------------|
| <u>8320 Guilford Road, Columbia,</u> <u>MD</u> (Address of principal executive offices) | <u>21046</u> (Zip code) |
|--|-----------------------------------|

(301) 854-3900
Registrant's telephone number, including area code

Not applicable
(Former name or former address, if changed since last report)

NOVAVAX, INC.
ITEMS TO BE INCLUDED IN THIS REPORT

ITEM 5. OTHER EVENTS.

On July 19, 2004, Novavax, Inc. closed its previously announced \$40 million in financings and its transaction with King Pharmaceuticals, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVAVAX, INC.

Date: July 20, 2004

By: /s/ Dennis W. Genge
Dennis W. Genge
Vice President and Chief Financial
Officer